nimodipine has been researched along with Depressive Disorder in 9 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
Depressive Disorder: An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Placebo-controlled, randomized, double-blind trial of nimodipine compared with placebo in out-of-hospital ventricular fibrillation." | 5.07 | Neuropsychological sequelae of cardiac arrest. ( Kajaste, S; Kaste, M; Roine, RO, 1993) |
| "Nimodipine pretreatment attenuated the perceived similarity of ketamine effects to ethanol as well as ketamine-induced euphoria and sedation." | 2.70 | Attenuation of ketamine effects by nimodipine pretreatment in recovering ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists. ( Burakov, AM; Fletcher, J; Grinenko, AY; Grinenko, NI; Krupitsky, EM; Krystal, JH; Petrakis, IL; Romanova, TN, 2001) |
| "Nimodipine (NMD) is a Ca(2+) channel blocker that has been extensively investigated for therapy of central nervous system (CNS) disorders." | 1.43 | Antidepressant-like activity of liposomal formulation containing nimodipine treatment in the tail suspension test, forced swim test and MAOB activity in mice. ( Freitas, RM; Moreno, LCGEAI; Rolim, HML; Santos-Magalhães, NS, 2016) |
| " When the calcium antagonist nimodipine was given at a dosage quickly escalated to 360 mg daily, the patient could be discharged in a state of complete remission after 26 days." | 1.29 | [Phase prevention in bipolar affective disorder with nimodipine. A case report]. ( Berger, M; Hellwig, B; Hesslinger, B; Riedel, H; Walden, J, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moreno, LCGEAI | 1 |
| Rolim, HML | 1 |
| Freitas, RM | 1 |
| Santos-Magalhães, NS | 1 |
| De León, OA | 1 |
| Taragano, FE | 2 |
| Bagnatti, P | 2 |
| Allegri, RF | 1 |
| Pazzaglia, PJ | 2 |
| Post, RM | 2 |
| Ketter, TA | 2 |
| George, MS | 2 |
| Marangell, LB | 2 |
| Roine, RO | 1 |
| Kajaste, S | 1 |
| Kaste, M | 1 |
| Hesslinger, B | 1 |
| Riedel, H | 1 |
| Hellwig, B | 1 |
| Walden, J | 1 |
| Berger, M | 1 |
| Callahan, AM | 1 |
| Frye, MA | 1 |
| Kimbrell, TA | 1 |
| Leverich, GS | 1 |
| Cora-Locatelli, G | 1 |
| Luckenbaugh, D | 1 |
| Allegri, R | 1 |
| Vicario, A | 1 |
| Lyketsos, CG | 1 |
| Krupitsky, EM | 1 |
| Burakov, AM | 1 |
| Romanova, TN | 1 |
| Grinenko, NI | 1 |
| Grinenko, AY | 1 |
| Fletcher, J | 1 |
| Petrakis, IL | 1 |
| Krystal, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Depression Occurring in the Setting of Cerebrovascular Risk -- A Pilot Study[NCT00781326] | Phase 4 | 9 participants (Actual) | Interventional | 2008-08-31 | Terminated (stopped due to Final cost of study medication was significantly greater than initial estimate,) | ||
| Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department[NCT04260607] | Phase 3 | 2 participants (Actual) | Interventional | 2020-01-14 | Terminated (stopped due to As a busy MTF we were unable to retain a health care provider with the appropriate expertise to buy-in to this study once the initiating PI left military service.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Hamilton Depression Rating Scale (24 item) measures symptoms of major depression. We report total score which is the sum of all items. Total score range is 0 to 76 with higher scores indicating more severe depression. We reports scores at end of Phase I for subjects completing the phase. (NCT00781326)
Timeframe: End of Phase I (at 24 weeks)
| Intervention | units on a scale (Mean) |
|---|---|
| Open Label Antidepressant | 9.5 |
6 trials available for nimodipine and Depressive Disorder
| Article | Year |
|---|---|
A double-blind, randomized clinical trial to assess the augmentation with nimodipine of antidepressant therapy in the treatment of "vascular depression".
Topics: Aged; Antidepressive Agents, Second-Generation; Argentina; Calcium Channel Blockers; Cerebrovascular | 2005 |
Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation.
Topics: Adult; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; | 1993 |
Neuropsychological sequelae of cardiac arrest.
Topics: Adult; Aged; Aged, 80 and over; Cognition; Depressive Disorder; Double-Blind Method; Female; Heart A | 1993 |
Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Calcium Channel Blockers; Carbamazepine; Depressive Disor | 1998 |
A double blind, randomized clinical trial assessing the efficacy and safety of augmenting standard antidepressant therapy with nimodipine in the treatment of 'vascular depression'.
Topics: Aged; Analysis of Variance; Antidepressive Agents; Calcium Channel Blockers; Cerebrovascular Disorde | 2001 |
Attenuation of ketamine effects by nimodipine pretreatment in recovering ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists.
Topics: Adult; Affect; Alcoholism; Anxiety; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Ty | 2001 |
3 other studies available for nimodipine and Depressive Disorder
| Article | Year |
|---|---|
Antidepressant-like activity of liposomal formulation containing nimodipine treatment in the tail suspension test, forced swim test and MAOB activity in mice.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tri | 2016 |
Response to nimodipine in ultradian bipolar cycling after amygdalohippocampectomy.
Topics: Antimanic Agents; Bipolar Disorder; Calcium Channel Blockers; Carbamazepine; Depressive Disorder; Fe | 2012 |
[Phase prevention in bipolar affective disorder with nimodipine. A case report].
Topics: Bipolar Disorder; Calcium Channel Blockers; Depressive Disorder; Dose-Response Relationship, Drug; D | 1996 |